Corsi Di Formazione Organizzati Da MSO - ANNO 2016

CORSO: Open issues in Oncology: New drugs for gastrointestinal, ovarian and lung cancer
Roma, 20-21 May 2016

Direttore: Prof. Antonio Russo
CREDITI ECM:

SCARICA IL PDF...

PROGRAMMA DEL CORSO (CLICCARE SULLE ICONE PER SCARICARE LE SLIDES)
VENERDI, 20 MAGGIO
10:00 Participant registration
10:30 PRESENTATION OF THE MEETING Antonio Russo, President of the Conference, (Palermo)
WELCOME TO THE CONFERENCE Clara Natoli, President of CINBO (Chieti)
Moderatori: Clara Natoli (Chieti), Pierosandro Tagliaferri (Catanzaro)
11:00 Guest Lectures:
Early tumor shrinkage and depth of response to anti-EGFR in colorectal cancer: helpful surrogates or meaningless endpoints? Marc Peeters (Anversa, BG)
Perspectives from translational research in gastrointestinal cancers Giampaolo Tortora (Padova)
12:00 Light Lunch
SESSION 1: Innovative strategies for gastrointestinal cancer
Moderatori: Corrado Ficorella (L’Aquila) Giuseppe Tonini (Roma)
15:00 New anti-angiogenic agents in colorectal cancer Daniele Santini (Roma)
15:20 Regorafenib in colorectal cancer: just a salvage treatment? Erika Martinelli (Napoli)
15:40 Intensive chemotherapy for pancreatic cancer Nicola Silvestris (Bari)
16:00 New chemotherapeutic agents for pancreatic cancer Davide Melisi (Verona)
16:20 Liquid biopsy in gastrointestinal cancers Marta Castiglia (Palermo)
16:40 Monoclonal antibodies in advanced gastric cancer Carlo Garufi (Pescara)
17:00 Discussion
17:15 Coffee break
17:30 Case reports and Discussion
Moderatori: C. Garufi (Pescara), B. Vincenzi (Roma)
Case report 1 Gemma Bruera (L’Aquila)
Case report 2 Antonio Galvano (Palermo)
SABATO, 21 MAGGIO
08:30 Guest Lecture:
Moderatori: Pierosandro Tagliaferri (Catanzaro)
The angiogenesis in ovarian cancer: bevacizumab and beyond Domenica Lorusso (Milano)
SESSION 2: Innovative strategies for ovarian cancer
Moderatori: Pierosandro Tagliaferri (Catanzaro), Silverio Tomao (Roma)
09:00 New chemotherapy to overcome platinum resistance Laura Cortesi (Modena)
09:20 Next generation techniques for biomarker identifi cation Ettore Capoluongo (Roma)
09:40 Preventive/predictive role of susceptibility gene mutations Bernardo Bonanni (Milano)
10:00 The clinical development of PARP inhibitors Enrico Ricevuto (L’Aquila)
10:20 Discussion
10:35 Case reports and Discussion
Moderatori: Enrico Ricevuto (L’Aquila), Sergio Rizzo (Palermo)
Case report 1 Lorena Incorvaia (Palermo)
Case report 2 Valentina Calò (Palermo)
11:05 Coffee break
11:20 Guest Lecture:
Moderatori: Franco Silvestris
The experience of Phase I trials in NSCLC: what do we have to expect for next years? Christian Rolfo (Anversa, BG)
SESSION 3 Innovation in 2nd line treatment for NSCLC
Moderatori: Clara Natoli (Chieti) Antonio Russo (Palermo)
11:50 Multi-target agents and angiogenesis Roberto Bianco (Napoli)
12:10 EGFR inhibitors for overcoming resistance Sergio Rizzo (Palermo)
12:30 The right place for ALK inhibitors Mario Roselli (Roma)
12:50 The new chance of immune checkpoint inhibitors Emilio Bria (Verona)
13:05 Discussion
13:20 Case reports and Discussion
Moderatori: M. Roselli (Roma), Anna Russo (Palermo)
Case report 1 Vito Barbieri (Catanzaro)
Case report 2 Francesco Passiglia (Palermo)